Latest Breaking News On - Tianjin medical university cancer institute - Page 5 : comparemela.com

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021 News provided by Share this article Share this article SAN FRANCISCO and SUZHOU, China, June 6, 2021 /PRNewswire/  Innovent Biologics, Inc. ( Innovent , HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 1 study in Chinese patients with advanced solid tumors were released today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2021. This is a Phase 1 study to evaluate the pharmacokinetic (PK), pharmacodynamic (PD) and safety of pemigatinib in Chinese patients (pts) with advanced malignancy. Moreover, potential efficacy of pemigatinib was explored in a broad spectrum of fibroblast growth factor receptor (FGFR) alteration in variety of cancer types. 12

United statesHong kongRhui zhouInnovent biologicsAdimab incyteYi baEli lillyIncyte pemazyreTianjin medical university cancer instituteAmerican society for clinical oncologyDrug administrationMd anderson cancer centerNational reimbursement drug listIncyte corporationClinical developmentInnovent biologics inc